Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ford Motor Company (F)’s New Models Are Hitting Their Stride

On Friday, Ford Motor Company (NYSE:F) reported strong February sales, with total deliveries up 9% year over year. One thing that was particularly notable about the report was that Ford achieved very strong sales of the Escape crossover and Fusion midsize sedan, two major products that were refreshed last year. While Ford generates most of its profit from the F-Series line of full-size pickups, the Escape and Fusion are critical products for Ford as it tries to diversify its product lineup. This is because the crossover and midsize car segments are two of the largest segments in the U.S. auto market (with the midsize segment recently becoming No. 1).

Ford Motor Company (NYSE:F)Month in review
Ford Motor Company (NYSE:F)’s F-Series trucks had another strong month in February, with sales up by 15% to 54,489. However, the Escape and Fusion were the real stars of the show. Escape sales grew 29% to 24,110, while Fusion sales grew 28% to 27,875. The Fusion’s gains were particularly remarkable given that the car’s February 2012 sales were already a record high for the month.

Both strong performances came after similarly good results in January. Escape and Fusion both generated record January sales this year, with Fusion up 65% to 22,399 vehicles. It seems that car buyers are shrugging off Ford Motor Company (NYSE:F)’s recent quality control problems: The new Escape was recalled four times in 2012, while the Fusion was recalled twice. Fortunately, there have been no new recalls for either model since early December, which should reassure customers.

Fusion gaining traction
While the Escape and Fusion results were both very impressive, the Fusion’s growth is probably more important at this point. The midsize car segment was the largest in the U.S. last year, and it has long been dominated by the Japanese automakers. Toyota Motor Corporation (ADR) (NYSE:TM) has built a massive following for its Camry midsize sedan, which has been the segment leader for a long time. The Honda Motor Co Ltd (ADR) (NYSE:HMC) Accord has also performed well and typically takes the second spot.  In 2012, the Fusion was the fourth-best-selling midsize car in the U.S., with 241,263 units sold. The Camry led the segment with 404,886 sold, followed by the Accord with 331,872, and the Nissan Altima with 302,934.

In 2013, Ford has vaulted over Nissan into the third spot in the midsize market: Fusion outsold the Altima for the second straight month in February. While Nissan’s February Altima sales total of 27,725 put it only 150 vehicles behind Fusion, it is still impressive that Ford has quickly closed what was a 20% gap in 2012. Moreover, the Honda Accord’s grip on the No. 2 slot is becoming tenuous; the Accord outsold the Fusion by only 124 units last month. The Toyota Camry maintained a significant lead with 31,270 units sold, but Fusion has certainly come within striking distance of the category leader.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.